Bristol-Myers Squibb Company which can be found using ticker (BMY) now have 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 90 and 55 suggesting an average Analsyt target price of $71.57. Given that the stocks previous close was at $56.12 this would indicate that there is a potential upside of 27.5%. There is a 50 day moving average of $59.02 and the 200 day moving average is $65.25. The company has a market cap of 118.26B. The stock price is currently at: 56.61 USD
The potential market cap would be $150,822,367,997 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 15.06, revenue per share of 21.44 and a 5.61% return on assets.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
